Pharmacokinetics of Ertapenem following Intravenous and Subcutaneous Infusions in Patients

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2010, p. 924–926 Vol. 54, No. 2
0066-4804/10/$12.00 doi:10.1128/AAC.00836-09

Copyright © 2010, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics of Ertapenem following Intravenous and
Subcutaneous Infusions in Patients

Denis Frasca,1,3 Sandrine Marchand,1,2,3 Franck Petitpas,1,3 Claire Dahyot-Fizelier,1,2,3
William Couet,1,2,3* and Olivier Mimoz1,2,3
INSERM, ERI-23, Poˆle Biologie Sante´, 40 Avenue du Recteur Pineau, Poitiers, France1; Universite´ de Poitiers,
UFR Me´decine-Pharmacie, 6 Rue de la Mile´trie, Poitiers, France2; and CHU Poitiers, 2 Rue de la Mile´trie,
Poitiers, France3
Received 22 June 2009/Returned for modification 28 July 2009/Accepted 18 November 2009

Steady-state pharmacokinetics of ertapenem were compared in patients after 1-g intravenous and subcutaneous
(s.c.) infusions. Bioavailability was 99%  18% after s.c. administration, but peaks were reduced by
about 1⁄2 (43  29 versus 115 28g/ml) and times to peak were delayed. Simulations based on unbound
concentrations show that time over the MIC should always be longer than 30% to 40% of the dosing interval,
suggesting that s.c. infusion could be an alternative in patients with reduced vascular access.

Deja un comentario

Este sitio usa Akismet para reducir el spam. Aprende cómo se procesan los datos de tus comentarios.